Home > Insider Trading > Filing (0000899243-18-031705)

Filing Details

Accession Number:: 0000899243-18-031705
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-12-26 16:14:41
Reporting Period:: 2018-12-21

Accepted Time:: 2018-12-26 16:14:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1008848	Acorda Therapeutics Inc	ACOR	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1279150	Scopia Capital Management Lp	152 West 57Th Street, 33Rd Floor New York NY 10019	No	No	Yes	No
1431207	Jeremy Mindich	152 West 57Th Street, 33Rd Floor New York NY 10019	No	No	Yes	No
1431208	Matthew Sirovich	152 West 57Th Street, 33Rd Floor New York NY 10019	No	No	Yes	No
1665995	Scopia Management, Inc.	152 West 57Th Street, 33Rd Floor New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-12-21	40,506	$13.24	5,643,926	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes

Footnotes

This Form 4 is filed jointly by Scopia Capital Management LP ("Scopia Management"), Scopia Management, Inc. ("Scopia Inc."), Matthew Sirovich and Jeremy Mindich. The securities reported in this Form 4 are held in the accounts of several private investment funds, including Scopia Long LLC, Scopia Windmill Fund LP, Scopia International Master Fund LP, Scopia PX LLC, Scopia PX International Master Fund LP, Scopia Partners LLC, Scopia Long International Master Fund LP, Scopia Long QP LLC, Scopia Health Care LLC, Scopia Health Care International Master Fund LP, Scopia LB LLC and Scopia LB International Master Fund LP (together, the "Investment Vehicles") for which Scopia Management serves as the investment manager. Each of the Investment Vehicles individually holds less than 10% of the outstanding shares of common stock of Acorda Therapeutics, Inc. (the "Issuer"). Scopia Management, as the investment manager of the Investment Vehicles,
(Continued from footnote 2) may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because Scopia Management has voting and investment power over such securities. In addition, Scopia Inc., as general partner of Scopia Management, and Matthew Sirovich and Jeremy Mindich, as Managing Directors of Scopia Inc., may be deemed to indirectly beneficially own the shares of common stock of the Issuer held directly by the Investment Vehicles because each of Scopia Inc., Mr. Sirovich and Mr. Mindich may be deemed to exercise voting and investment power over such securities. Further, Messrs. Sirovich and Mindich may be deemed to have a pecuniary interest in a portion of the securities held directly by the Investment Vehicles due to the right of an affiliate of Scopia Management to receive performance-based allocations and due to their investments in the Investment Vehicles.
Each of Scopia Management, Scopia Inc. and Messrs. Sirovich and Mindich disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Scopia Management, Scopia Inc. or Messrs. Sirovich and Mindich is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.